January 30, 2019
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
Read More
January 30, 2019
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
Read More
January 30, 2019
Sutent Rechallenge In mRCC Patients
Read More
January 30, 2019
Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting
Read More
X